Nature Communications (Jul 2022)
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma
- Heathcliff Dorado García,
- Fabian Pusch,
- Yi Bei,
- Jennifer von Stebut,
- Glorymar Ibáñez,
- Kristina Guillan,
- Koshi Imami,
- Dennis Gürgen,
- Jana Rolff,
- Konstantin Helmsauer,
- Stephanie Meyer-Liesener,
- Natalie Timme,
- Victor Bardinet,
- Rocío Chamorro González,
- Ian C. MacArthur,
- Celine Y. Chen,
- Joachim Schulz,
- Antje M. Wengner,
- Christian Furth,
- Birgit Lala,
- Angelika Eggert,
- Georg Seifert,
- Patrick Hundsoerfer,
- Marieluise Kirchner,
- Philipp Mertins,
- Matthias Selbach,
- Andrej Lissat,
- Frank Dubois,
- David Horst,
- Johannes H. Schulte,
- Simone Spuler,
- Daoqi You,
- Filemon Dela Cruz,
- Andrew L. Kung,
- Kerstin Haase,
- Michela DiVirgilio,
- Monika Scheer,
- Michael V. Ortiz,
- Anton G. Henssen
Affiliations
- Heathcliff Dorado García
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Fabian Pusch
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Yi Bei
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Jennifer von Stebut
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Glorymar Ibáñez
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Kristina Guillan
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Koshi Imami
- Max Delbrück Center for Molecular Medicine
- Dennis Gürgen
- Experimental Pharmacology and Oncology (EPO)
- Jana Rolff
- Experimental Pharmacology and Oncology (EPO)
- Konstantin Helmsauer
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Stephanie Meyer-Liesener
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Natalie Timme
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Victor Bardinet
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Rocío Chamorro González
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Ian C. MacArthur
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Celine Y. Chen
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Joachim Schulz
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Antje M. Wengner
- Bayer AG
- Christian Furth
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Birgit Lala
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Angelika Eggert
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Georg Seifert
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Patrick Hundsoerfer
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Marieluise Kirchner
- Max Delbrück Center for Molecular Medicine
- Philipp Mertins
- Max Delbrück Center for Molecular Medicine
- Matthias Selbach
- Max Delbrück Center for Molecular Medicine
- Andrej Lissat
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Frank Dubois
- Institute of pathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- David Horst
- Institute of pathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Johannes H. Schulte
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Simone Spuler
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Daoqi You
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Filemon Dela Cruz
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Andrew L. Kung
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Kerstin Haase
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- Michela DiVirgilio
- Max Delbrück Center for Molecular Medicine
- Monika Scheer
- Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin
- Michael V. Ortiz
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Anton G. Henssen
- Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin
- DOI
- https://doi.org/10.1038/s41467-022-32023-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
Alveolar rhabdomyosarcoma is a clinically challenging disease due to the lack of druggable targets. Here the authors show preclinical evidence for ATR inhibitors as a therapeutic option for alveolar rhabdomyosarcoma.
